Condition: Leukemia, Myeloid, Acute · Refractory AML · Relapsed Adult AML · Sponsor: Aptose Biosciences Inc.
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.
This description comes directly from the study's public registry record.
Rafael Bejar, MD, PhD · 858-401-6852 · rbejar@aptose.com
Always discuss trial participation with your own doctor first.
| The Kirklin Clinic of UAB Hospital | Birmingham, Alabama, United States | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Active Not Recruiting |
| University of California Irvine | Irvine, California, United States | Recruiting |
| UCSD Moores Cancer Center | La Jolla, California, United States | Active Not Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| University of California, Davis | Sacramento, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Miami - Miller School of Medicine | Miami, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Active Not Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Active Not Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03850574